Mach (M7T.AX) traded up 4.17 % during a 24 hours period ending at 06:46 PM Central Europe on Tuesday 27th. One Mach stock can currently be bought for about AUD 0.26 on popular exchanges. Current supply of Mach stocks is 225.6 mn. Mach has a current market capitalization of AUD 56.4 mn and approximately AUD 74 k worth of Mach was traded on exchanges in the last 24 hours. Since last month end, Mach has traded 8.7 % up. Simple moving average of last 200 days is at AUD 0.3. The highest price of past 52 weeks was recorded at AUD 0.68 on 01/05/2026. 52 weeks low was at AUD 0.21 on 10/15/2026.
Here is how related stocks have performed in the past 24 hours:
Nordic (NNL.AX) traded down -2.94 % and now trades at AUD 0.17. Current market capitalisation for Nordic is AUD 64.8 mn.
Experience (EXP.AX) traded flat 0 % and now trades at AUD 0.09. Current market capitalisation for Experience is AUD 65.7 mn. Experience has a current price to earnings ratio of 108.75. Experience Co Limited reported a modestly stronger first quarter of fiscal year 2027. Revenue and underlying earnings grew compared to the same period a year earlier, with the Skydiving segment leading the gain. Volume performance varied across sites, influenced by weather and visitor trends, but overall the company achieved higher tandem and adventure bookings. Margin improvement was noted, particularly within Skydiving, where higher volumes offset pressure in the Adventure Experiences segment. The company also highlighted progress in negotiations with Inflite Group and forthcoming updates at its annual general meeting. During the Golden Week trading period, both Skydiving Australia and New Zealand recorded strong activity, while Reef Unlimited experienced solid bookings despite regional visitation impacts. Treetops Adventure focused on yield amid softer volumes, maintaining growth driven by higher average revenue per customer.
Patronus (PTN.AX) traded up 4.76 % and now trades at AUD 0.04. Current market capitalisation for Patronus is AUD 65.1 mn.
Ardea (ARL.AX) traded up 1.64 % and now trades at AUD 0.3. Current market capitalisation for Ardea is AUD 65.9 mn. ARDEA RESOURCES LTD is preparing for its 2026 annual general meeting, during which shareholders will consider a series of governance and remuneration matters. The company will present its financial statements and directors’ report for the year ended 30 June 2026 and seek approval of a remuneration report that has been deemed reasonable by the board. Shareholders will also vote on the re‑election of a director who is retiring by rotation, and on the issuance of shares to two non‑executive directors as partial payment of their fees for the 2027 financial year. In addition, a resolution to approve a 10 % placement facility under ASX Listing Rule 7.1A will be tabled, allowing the company to raise capital for expansion projects. Finally, the board will request shareholder consent to grant performance rights to the chief executive officer and to non‑executive directors, aligning executive and board remuneration with share‑price performance. The meeting, scheduled for 27 November 2026, will be held in Sydney and will be open to shareholders via proxy or in person.
Neurizon Therapeutics (NUZ.AX) traded up 7.32 % and now trades at AUD 0.09. Neurizon Therapeutics has a market capitalisation of AUD 67.4 mn. Neurizon Therapeutics Limited will convene its annual general meeting on 25 November 2026 in a hybrid format, allowing shareholders to attend in person or online. The meeting will review the company’s 2026 financial statements and director remuneration report, and present several resolutions for shareholder approval. Key items include the election of Dr Ross Murdoch to the board, the grant of options to the new non‑executive director, and a proposal to issue convertible notes to Obsidian Global GP, LLC. Shareholders will also consider a special resolution to increase the company’s equity‑issue capacity under Listing Rule 7.1A. The board recommends voting in favour of all proposals, and the chair intends to support the resolutions on the day. Shareholders are encouraged to submit proxies early to participate fully in the vote.
About Mach
Mach7 Technologies Ltd. is an Australian health care technology company that specializes in designing and developing healthcare software solutions. The company offers several key products, including an Enterprise Imaging Platform, Vendor Neutral Archive, Communication Workflow Engine, and Managed Data Solutions. Mach7 Technologies operates in Port Melbourne and is listed on the ASX All Markets stock exchange. The company went public on November 30, 2005.